Cerenovus, part of the Johnson & Johnson Medical Devices Companies, has announced that the first patients have been treated with the BRAVO Flow Diverter, following recent CE mark approval for the device to be used in the treatment of intracranial aneurysms.
“The BRAVO Flow Diverter is a welcome addition to the existing treatment options for intracranial aneurysms” said Patrick Brouwer senior consultant neurointerventionalist at Karolinska University Hospital, Stockholm, Sweden and Evaluator for the BRAVO Flow Diverter. “I am impressed with the overall handling of the device, in particular the ease of use, opening functionality and stability of the device placement.”
Flow diverters divert blood flow from the aneurysm and promote healing thereby reducing the risk of rupture, a main cause of haemorrhagic stroke. Accurate positioning of the flow diverter and effective delivery and deployment are important factors in the successful treatment of intracranial aneurysms. The design of the BRAVO Flow Diverter reflects these requirements and aims to provide surgeons with confidence when positioning and deploying the device, contributing to complete diversion effect.
“We are delighted with the clinician feedback and patient outcomes from the early evaluation cases” said Daniella Cramp, worldwide president, Cerenovus. “After an extensive research and development process we are proud to see that our latest innovation is enabling patients to live a life free from the burden of haemorrhagic stroke.”
The device is currently not approved for use in the USA.
